{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:55Z","timestamp":1772119315356,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["174281"],"award-info":[{"award-number":["174281"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009068","name":"Universit\u00e4t Bern","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evidence on the use and efficacy of medical cannabis for children is limited. We examined clinical and epidemiological characteristics of medical cannabis treatment and caregiver-reported effects in children and adolescents in Switzerland. We collected clinical data from children and adolescents (&lt;\u200918\u00a0years) who received \u03949-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of the two between 2008 and 2019 in Switzerland. Out of 205 contacted families, 90 agreed to participate. The median age at the first prescription was 11.5\u00a0years (interquartile range (IQR) 6\u201316), and 32 patients were female (36%). Fifty-one (57%) patients received CBD only and 39 (43%) THC. Patients were more likely to receive THC therapy if one of the following symptoms or signs were present: spasticity, pain, lack of weight gain, vomiting, or nausea, whereas seizures were the dominant indication for CBD therapy. Improvements were reported in 59 (66%) study participants. The largest treatment effects were reported for pain, spasticity, and frequency of seizures in participants treated with THC, and for those treated with pure CBD, the frequency of seizures. However, 43% of caregivers reported treatment interruptions, mainly because of lack of improvement (56%), side effects (46%), the need for a gastric tube (44%), and cost considerations (23%).<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    : The effects of medical cannabis in children and adolescents with chronic conditions are unknown\u00a0except for rare seizure disorders, but the caregiver-reported data analysed here may justify trials of medical cannabis with standardized concentrations of THC or CBD to assess its efficacy in the young.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              <jats:italic>\u2022 The use of medical cannabis (THC and CBD) to treat a variety of diseases among children and adolescents is increasing.<\/jats:italic>\n                              <jats:italic>\u2022 In contrast to adults, there is no evidence to support the use of medical cannabis to treat chronic pain and spasticity in children, but substantial evidence to support the use of CBD in children with rare seizure disorders.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              <jats:italic>\u2022 This study provides important insights into prescription practices, dosages, and treatment outcomes in children and adolescents using medical cannabis data from a real-life setting.<\/jats:italic>\n                              <jats:italic>\u2022 The effects of medical cannabis in children and adolescents with chronic conditions shown in our study support trials of medical cannabis for chronic conditions.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-021-04202-z","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T04:02:52Z","timestamp":1627272172000},"page":"335-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland"],"prefix":"10.1007","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7915-3194","authenticated-orcid":false,"given":"Kathrin","family":"Z\u00fcrcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilca","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela E.","family":"Eigenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-851X","authenticated-orcid":false,"given":"Martina L.","family":"Reichmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-5132","authenticated-orcid":false,"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-4835","authenticated-orcid":false,"given":"Lukas","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"2","key":"4202_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013) The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33(2):195\u2013209","journal-title":"Pharmacotherapy"},{"key":"4202_CR2","doi-asserted-by":"crossref","unstructured":"Wong SS, Wilens TE (2017) Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 140(5)","DOI":"10.1542\/peds.2017-1818"},{"issue":"9","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/dmcn.14548","volume":"62","author":"C Fairhurst","year":"2020","unstructured":"Fairhurst C, Kumar R, Checketts D, Tayo B, Turner S (2020) Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev Med Child Neurol 62(9):1031\u20131039","journal-title":"Dev Med Child Neurol"},{"key":"4202_CR4","doi-asserted-by":"crossref","unstructured":"Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV et al (2016) Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2(2):Cd007786","DOI":"10.1002\/14651858.CD007786.pub3"},{"issue":"6","key":"4202_CR5","first-page":"946","volume":"79","author":"HS Chan","year":"1987","unstructured":"Chan HS, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79(6):946\u2013952","journal-title":"Pediatrics"},{"issue":"4","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6(4):237\u2013249","journal-title":"Curr Drug Saf"},{"issue":"20","key":"4202_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M et al (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New Eng J Med 378(20):1888\u20131897","journal-title":"New Eng J Med"},{"issue":"21","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New Eng J Med 376(21):2011\u20132020","journal-title":"New Eng J Med"},{"issue":"14","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL et al (2018) Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 90(14):e1204\u2013e1211","journal-title":"Neurology"},{"issue":"10125","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C et al (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 391(10125):1085\u20131096","journal-title":"Lancet (London, England)"},{"issue":"6","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36(6):1219\u20131226","journal-title":"Neuropsychopharmacology"},{"key":"4202_CR12","doi-asserted-by":"crossref","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO et al (2019) Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 9(1521)","DOI":"10.3389\/fphar.2018.01521"},{"issue":"1","key":"4202_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","volume":"9","author":"L Bar-Lev Schleider","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V (2019) Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 9(1):200","journal-title":"Sci Rep"},{"key":"4202_CR14","unstructured":"Bundesrat (2018) Cannabis f\u00fcr Schwerkranke: Bericht des Bundesrates in Erf\u00fcllung der Motion 14.4164, Kessler, 11.12.2014. Bundesrat"},{"key":"4202_CR15","unstructured":"Bundesrat (2020) 812.121 Bundesgesetz vom 3. Oktober 1951 \u00fcber die Bet\u00e4ubungsmittel und die psychotropen Stoffe (Bet\u00e4ubungsmittelgesetz, BetmG) Bern Bundesrat; Available from: https:\/\/www.admin.ch\/opc\/de\/classified-compilation\/19981989\/index.html"},{"key":"4202_CR16","unstructured":"Praxis Suchtmedizin Schweiz (2018) CBD St. Gallen Praxis Suchtmedizin Schweiz; Available from: https:\/\/praxis-suchtmedizin.ch\/praxis-suchtmedizin\/index.php\/de\/cannabis\/cbd"},{"key":"4202_CR17","doi-asserted-by":"crossref","unstructured":"Kilcher G, Zwahlen M, Ritter C, Fenner L, Egger M (2017) Medical use of cannabis in Switzerland: analysis of approved exceptional licences. Swiss Med Wkly 147:w14463","DOI":"10.4414\/smw.2017.14463"},{"issue":"2","key":"4202_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J biomed inform"},{"key":"4202_CR19","unstructured":"Praxis Suchtmedizin Schweiz (2019) \u00dcbersicht der gebr\u00e4uchlichsten Cannabinoide in der Schweiz St.Gallen: Praxis Suchtmedizin Schweiz; Available from: https:\/\/www.praxis-suchtmedizin.ch\/praxis-suchtmedizin\/images\/stories\/cannabinoide\/20191023_praeparate-galenik-hersteller-dosierung-kosten.pdf"},{"key":"4202_CR20","unstructured":"Fankhauser M. Kompendium Cannabisprodukte der Bahnhof Apotheke Langnau AG LangnauNA. Available from: https:\/\/panakeia.ch\/fileadmin\/user_upload\/Downloads\/Cannabis\/1_Kompendium__Cannabispraeparate_.pdf"},{"issue":"3","key":"4202_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","volume":"29","author":"BE Porter","year":"2013","unstructured":"Porter BE, Jacobson C (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29(3):574\u2013577","journal-title":"Epilepsy Behav"},{"key":"4202_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","volume":"35","author":"M Tzadok","year":"2016","unstructured":"Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S et al (2016) CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure 35:41\u201344","journal-title":"Seizure"},{"issue":"2","key":"4202_CR23","first-page":"76","volume":"19","author":"M Hausman-Kedem","year":"2017","unstructured":"Hausman-Kedem M, Kramer U (2017) Efficacy of medical cannabis for treatment of refractory epilepsy in children and adolescents with emphasis on the Israeli experience. Isr Med Assoc J: IMAJ 19(2):76\u201378","journal-title":"The Israel Medical Association journal : IMAJ"},{"key":"4202_CR24","doi-asserted-by":"crossref","unstructured":"de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E (2020) Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav 102:106635","DOI":"10.1016\/j.yebeh.2019.106635"},{"issue":"6","key":"4202_CR25","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ejpn.2016.07.021","volume":"20","author":"M Kuhlen","year":"2016","unstructured":"Kuhlen M, Hoell JI, Gagnon G, Balzer S, Oommen PT, Borkhardt A et al (2016) Effective treatment of spasticity using dronabinol in pediatric palliative care. Eur J Paediatr Neurol 20(6):898\u2013903","journal-title":"Eur J Paediatr Neurol"},{"key":"4202_CR26","doi-asserted-by":"publisher","first-page":"088307381877302","DOI":"10.1177\/0883073818773028","volume":"33","author":"S Libzon","year":"2018","unstructured":"Libzon S, Bar-Lev Schleider L, Saban N, Levit L, Tamari Y, Linder I et al (2018) Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. J Child Neurol 33:088307381877302","journal-title":"J Child Neurol"},{"issue":"9395","key":"4202_CR27","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"J Zajicek","year":"2003","unstructured":"Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet 362(9395):1517\u20131526","journal-title":"The Lancet"},{"key":"4202_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ctim.2017.08.010","volume":"34","author":"VP da Rovare","year":"2017","unstructured":"da Rovare VP, Magalh\u00e3es GPA, Jardini GDA, Beraldo ML, Gameiro MO, Agarwal A et al (2017) Cannabinoids for spasticity due to multiple sclerosis or paraplegia: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med 34:170\u2013185","journal-title":"Complement Ther Med"},{"issue":"4","key":"4202_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"DT Wade","year":"2004","unstructured":"Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler J 10(4):434\u2013441","journal-title":"Mult Scler J"},{"issue":"24","key":"4202_CR30","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jama 313(24):2456\u20132473","journal-title":"Jama"},{"key":"4202_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","volume":"96","author":"D Samanta","year":"2019","unstructured":"Samanta D (2019) Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatric neurology 96:24\u201329","journal-title":"Pediatric neurology"},{"key":"4202_CR32","unstructured":"Sundheds- og \u00c6ldreministeriet (2017) Vejledning om l\u00e6gers behandling af patienter med medicinsk cannabis omfattet af fors\u00f8gsordningen Copenhagen: Sundheds- og \u00c6ldreministeriet; Available from: https:\/\/www.retsinformation.dk\/eli\/retsinfo\/2018\/9000"},{"key":"4202_CR33","unstructured":"Queensland Health (2018) Clinical Guidance: for the use of medicinal cannabis products in Queensland Queensland: Queensland Health; Available from: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0023\/634163\/med-cannabis-clinical-guide.pdf"},{"key":"4202_CR34","unstructured":"Therapeutic Goods Administration (2020) Medicinal cannabis - guidance documents Woden ACT: Australian Government Department of Health; Available from: https:\/\/www.tga.gov.au\/node\/732373"},{"issue":"9","key":"4202_CR35","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/epi.13089","volume":"56","author":"J Riechmann","year":"2015","unstructured":"Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C et al (2015) Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia 56(9):1388\u20131397","journal-title":"Epilepsia"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04202-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-021-04202-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04202-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T21:15:55Z","timestamp":1642194955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-021-04202-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s00431-021-04202-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-517522\/v1","asserted-by":"object"}]},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"13 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Cantonal Ethics Committee Bern (2019\u201300,049), Switzerland, approved this study. Written informed consent was obtained from the caregivers of each child or adolescent younger than 14\u00a0years. Among older adolescents, either the adolescent or the caregivers gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written consent for publication was obtained from the caregivers of each child or adolescent younger than 14\u00a0years. Among older adolescents, either the adolescent or the caregivers gave written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF is the owner of the Bahnhof Apotheke Langnau AG, which produces and distributes medical cannabis-based preparations to patients upon medical prescription. DE works as a pharmacist in the same pharmacy and is a board member of the Swiss Society of Cannabis in Medicine. MF and DE had no role in study design and data analysis. All other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}